[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.130.145. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
June 1986

Thymostimulin in Treatment of Psoriasis

Author Affiliations

Sección de Dermatología Hospital General del Valle de Hebrón Universidad Autónoma 08035 Barcelona, Spain

Arch Dermatol. 1986;122(6):624. doi:10.1001/archderm.1986.01660180024004
Abstract

To the Editor.—  Thymostimulin (TMS), a calf thymus extract, can be successfully used in the treatment of patients with viral diseases and cell-mediated immune defects. A significant reduction in the number of total circulating T lymphocytes has been observed in patients with psoriasis, while the number of circulating B cells was normal and there was an increase of null cells.1 In skin, the dermal mononuclear infiltrate consists almost exclusively of T lymphocytes and macrophages.2Recently, Baker et al3 studied the relationship between T-cell populations in blood and in skin of psoriatic patients as well as the correlation with the chronicity, type, and extent of the skin lesions. In blood from patients with guttate psoriasis (GP), the reduction in the number of T lymphocytes was due entirely to a decrease in T helper-inducer (Th) cells. In chronic plaque (CP) psoriasis, both Th and suppressor-cytotoxic T-lymphocyte (Ts) subset were

First Page Preview View Large
First page PDF preview
First page PDF preview
×